Clelia Di Salvo

University of Pisa

H指数:10

被引数:277

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Perianal fistulizing Crohn’s disease: emerging biology, therapeutics, and roadmap for precision treatment

肛周瘘性克罗恩病：新兴生物学、治疗策略和精准治疗路线图

Trends in Pharmacological Sciences

IF19.9

2026-10-200

PRE

Back to the future, the need for early stage green optimization of drug candidates: PIGAs as a case study

回归未来：药物候选物早期绿色优化的必要性：以PIGAs为例

Sustainable Chemistry and Pharmacy

IF5.8

2026-09-010

PRE

Diosmin Attenuates Age-Associated Vascular Oxidative Stress and Endothelial Dysfunction in Aged Rats

diosmin缓解老龄大鼠与年龄相关的血管氧化应激和内皮功能障碍

Foods

IF5.1

2026-08-110

A Novel Mixture Containing Enterococcus lactis SF68® Restores Gut Barrier Integrity in a DSS-Induced Murine Model of Post-Colitis IBS-like Symptoms

International Journal of Molecular Sciences

IF4.9

2026-07-260

Pharmacological Blockade of NLRP3 Counteracts Sarcopenia in a Mouse Model of Mild Cognitive Impairment Via Modulation of Gut-Muscle Axis

通过调节肠道-肌肉轴，药理学阻断NLRP3可对抗轻度认知障碍小鼠模型中的肌肉减少症

Journal of Pharmacology and Experimental Therapeutics

IF3.8

2026-05-010

PRE

Purinergic Pathway Dysregulation in IBD and Pharmacological Efficacy of Dual P2X4R/P2X7R Blockade in Colitis

炎症性肠病中嘌呤能通路失调及双重P2X4R/P2X7R阻断在结肠炎中的药理效果

Journal of Pharmacology and Experimental Therapeutics

IF3.8

2026-05-010

PRE

Gut Microbiota Manipulation by Probiotic Lacticaseibacillus paracasei DG I1572 as New Therapeutical Strategy to Counteract Vascular Inflammaging

Molecular Nutrition & Food Research

IF4.2

2026-02-010

PRE

The right drug at the right time: key to IBD success

合适的药物在合适的时间：IBD治疗成功的关键

Trends in Molecular Medicine

IF13.8

2025-11-270

PRE

Enteric glial NLRP3 inflammasome contributes to gut mucosal barrier alterations in a mouse model of diet-induced obesity

ACTA PHYSIOLOGICA

IF5.6

2024-09-171

Lactiplantibacillus plantarum HEAL9 attenuates cognitive impairment and progression of Alzheimer's disease and related bowel symptoms in SAMP8 mice by modulating microbiota-gut-inflammasome-brain axis

FOOD & FUNCTION

IF5.4

2024-01-015

FOOD & FUNCTION

IF5.4

2024-01-010

Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2023-08-275

Enteric a-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology (Vol 8, 9, 2022)

NPJ PARKINSONS DISEASE

IF8.2

2023-06-022

OAAI

Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity

METABOLITES

IF3.7

2023-03-095

OAAI

The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice

FRONTIERS IN MICROBIOLOGY

IF4.5

2022-12-168

OAAI

Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology

NPJ PARKINSONS DISEASE

IF8.2

2022-01-1251

OAAI

P2X4 Receptor Antagonists Exert Anti-Inflammatory Effects via NLRP3 Inflammasome in a Murine Model of Colitis

P2X4受体拮抗剂通过NLRP3炎性小体在结肠炎小鼠模型中发挥抗炎作用

ACS Pharmacology & Translational Science

IF3.7

PRE

Clelia Di Salvo

个人简介

教育背景

工作经历

荣誉奖项

研究方向